top of page

Mwandishi

Mhariri:

ULY CLINIC

Dkt. Peter A, MD

18 Aprili 2021, 11:28:40

Emtricitabine na ujauzito

Emtricitabine na ujauzito

Emtricitabine ni dawa moja ya ARV inayotumika pamoja na dawa zingine kwenye matibabu ya Maambukizi ya virusi vya UKIMWI. Taarifa za wanyama zinaonyesha kuwepo kwa hatari kiasi, hata hivyo taarifa chache zilizopo kuhusu matumizi kwa binadamu zinazuia kutoa majibu ya uhakika kuhusu madhara kwa kijusi na kichanga tumboni. Dawa hii isisitishwe endapo imeshauriwa kutumika kipindi cha ujauzito.


Matumizi wakati wa ujauzito


Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni


Inapatana na ujauzito- faida kwa mama >>hatari kwa Kijusi-kichanga tumboni ina maaga gani?

Kunaweza kuwa au kutokuwa na uzoefu wa matumizi ya dawa hii kwa binadamu, lakini faida ni kubwa zaidi zikitumiwa na mama kuliko madhara yanayofahamika au kutofahamika kuwa yanaweza kutokea kwa kijusi-kichanganya tumboni. Kwa mama dawa zinazidi madhara yanayofahammika. Taarifa za uzazi kwa wanyama hazina mahusiano


Matumizi kwa mama anayenyonyesha


Haipatani na unyoyenyeshaji


Haipatani na unyoyenyeshaji ina maana gani?

Kunawezekana kuwa hakuna taarifa za uzoefu wa matumizi ya dawa hii kwa mama anayenyonyesha. Hata hivyo mkusanyiko wa taarifa zinaonyesha kuwa dawa huweza kuwa sumu kali kwa kichanga, au haishauriwi kunyonyesha endapo dawa itahitajika kutumika kwa mama mwenye anayehitajika kutumia dawa hii. Mama anatakiwa asinyonyeshe anapotumia dawa hii au akiwa na ugonjwa unaotakiwa kutumia dawa hii.

ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha  vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.

Imeboreshwa,

4 Juni 2025, 18:50:55

​

  1. Product information. Emtriva. Gilead Sciences; 2004.

  2. Szczech GM, et al. Reproductive toxicology profile of emtricitabine in mice and rabbits. Reprod Toxicol. 2003;17:95–108.

  3. Carpenter CCJ, et al. Antiretroviral therapy for HIV infection in 1996. JAMA. 1996;276:146–54.

  4. Minkoff H, et al. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol. 1997;176:478–89.

  5. Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol. 2003;101:797–810.

  6. Hirt D, et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother. 2009;53:1067–73.

  7. Stek AM, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012;13:226–35.

  8. Colbers APH, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS. 2013;27:739–48.

  9. Furco A, Gosrani B, Nicholas S, Williams A, Braithwaite W, Pozniak A, Taylor G, Asboe D, Lyall H, Shaw A, Kapembwa M. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS. 2009;23:434–5.

  10. Benaboud S, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA study, step 2. Antimicrob Agents Chemother. 2011;55:1315–7.

  11. Brown ZA, et al. Antiviral therapy in pregnancy. Clin Obstet Gynecol. 1990;33:276–89.

  12. De Martino M, et al. HIV-1 transmission through breast-milk: appraisal of risk according to duration of feeding. AIDS. 1992;6:991–7.

  13. Van de Perre P. Postnatal transmission of human immunodeficiency virus type 1: the breast feeding dilemma. Am J Obstet Gynecol. 1995;173:483–7.

bottom of page